Latest News

Americans are fatter than ever and processed food is to blame
Before diving into this article we need to clarify how being obese is measured. There are many ways to...
Read more
Through the Microscope updates
An important feature of Through the Microscope is the animations that depict important processes. Often...
Read more
Obesity and the Microbiome
A large body of evidence is emerging showing that the microbiome has a role in obesity and I cover some...
Read more
New updates to Why Microbes Matter
Chapters 4, 5, 8, 10, and 14 of Why Microbes Matter have been updated to reflect some new information...
Read more
The very real danger of alfatoxins
Food products, especially harvested grains, need to be stored carefully. Proper management means storing...
Read more


A new avenue of attack against drug resistance pathogens

Created by paustian on Oct 3, 2016, 8:45 PM

  Some pathogens are becoming resistant to many of the treatments we have for them. It is serious enough that the World Health Organization has declared antimicrobial resistance worthy of attention rivaling that of climate change. Strains of Staphylococcus aureus and Neisseria Gonorrhoeae are feared to be close to escaping treatment with antimicrobials. Researchers around the world are racing to discover new treatments for these multi-drug resistant pathogens. Shu Lam, a 25-year-old PhD student at the University of Melbourne in Australia, is pursuing a novel approach. Her research, reported in the journal Nature Microbiology describes the creation of peptide nanoparticles that can kill bacteria, and yet have extremely low toxicity. In addition it appears to be extremely difficult for the bacterium to develop resistance because the particles are toxic to bacteria by a number of unrelated modes of action.

The research is in its very early stages. Many questions need to be answers before it is clear whether this will be an effective treatment.

  1. What are the long term effects of using these compounds in the human body? How low is the toxicity to humans?
  2. What happens to the non-pathogens, the microbiome, when these treatments are administered?
  3. Do these compounds degrade in the environment? What are their half-lives?
  4. What is the range of toxicity for other microbes (or macrobes)?

These and many more will probably have to be answered before we can gauge their effectiveness. A very promising start, in any case.